What Happened
A market analysis published October 30 in JAMA Health Forum set out to answer a narrow question: now that federal regulators have declared the semaglutide and tirzepatide shortages over, what is actually left of the compounded GLP-1 business?
The answer is most of it. Researchers audited 75 brick-and-mortar businesses in two states with heavy demand for weight-loss drugs. Sixty-nine — 92.0% — reported offering compounded semaglutide. Sixty-five (86.7%) reported compounded tirzepatide. Seven (9.3%) advertised an oral compounded formulation.
The products are also rarely straight copies. Forty-four of the 75 businesses (58.7%) compounded their GLP-1 with an added ingredient. B vitamins were the most common additive, appearing at 42 businesses (56.0%), followed by levocarnitine at five (6.7%) and glycine at four (5.3%).
The supply chain is where the findings sharpen. Tracing them back found 23 compounding facilities. Of the 21 with available records, four (19.0%) were not licensed to perform sterile compounding, and four had been subject to disciplinary action — an FDA warning letter or a state board of pharmacy action.
Two days later, The Regulatory Review devoted its Saturday Seminar to the same question. Contributors split along a familiar line: pharmacy researchers led by Washington State University's Joshua Neumiller pointed to variable concentrations, dosing errors and semaglutide salt forms that differ from the approved ingredient; Joseph Mattingly II of Utah and Rena Conti of Boston University argued compounded products sit in an advertising gray zone, and proposed prescription-drug ad standards plus an independent body to set the shortage list; quality director Jared Dudding countered that compounding preserves access when brand-name treatment runs past $1,000 a month.
Who Is Affected
Patients paying cash for weight management, the clinicians prescribing to them, and the pharmacies supplying both. It also reaches researchers: the same storefront model sells research-labeled peptides without prescriptions or sterility oversight.
Timeline
- Late 2022 — Injectable GLP-1s enter the FDA drug shortage list; compounding of copies becomes permissible.
- February 2025 — FDA declares both shortages resolved. Copies of marketed drugs lose their exemption; 503B outsourcing facilities receive a wind-down window.
- October 19, 2026 — Apothecary Pharma recalls 22 vials of compounded tirzepatide nationwide over sterility concerns.
- October 30, 2026 — JAMA Health Forum publishes the post-shortage market audit.
- October 31, 2026 — Regulatory Review seminar weighs enforcement against access.
What This Means for Researchers
Three distinctions carry the legal weight. First, "essentially a copy" versus "clinically different" — an additive only counts if a prescriber documents a real clinical need, not a marketing preference. Second, additives such as B vitamins, glycine or BPC-157 have no combination trials behind them, so potency and stability are assumptions. Third, a 503B facility may compound in volume without collecting patient prescriptions, which is why licensure and inspection history matter more than the label.
How to Verify Your Peptides
- Ask for a certificate of analysis from an accredited third-party lab, and confirm the lot number on the vial matches the certificate.
- Check sterility and licensure — a supplier's state board record is public.
- Compare the labeled concentration against the tested concentration; that single step catches most of the dosing errors described in the literature.
- Our testing guides walk through reading a COA and spotting a recycled one.
Safe Alternatives
For patients, an FDA-approved GLP-1 prescribed and monitored by a clinician remains the reference standard. For research use, source from suppliers that publish lot-level testing — our vendor directory and peptide reference pages list what each product is and what evidence exists.
Sources
Industry reports; regulatory announcements; peer-reviewed analysis in JAMA Health Forum (October 30, 2026) and Diabetes Care; policy commentary published by The Regulatory Review (October 31, 2026).